Search / Trial NCT00000652

A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection

Launched by NATIONAL CANCER INSTITUTE (NCI) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of December 10, 2023

Completed

Keywords

Didanosine Drug Evaluation Drug Therapy, Combination Zidovudine

Description

New approaches to using available agents may provide increased or improved treatment options for AIDS. Combination therapy is expected to play a major role in improving survival and quality of life for HIV-infected individuals. AZT and ddI are two agents that have been most extensively evaluated and for which the evidence for antiretroviral effectiveness is strongest. Patients take AZT and ddI on an empty stomach; ddI is taken 2 minutes after taking antacid. Part A patients receive AZT plus ddI each at ranging doses. Patients in part B may receive a higher dose of ddI than patients in part...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Corticosteroids for treatment of lymphocytic interstitial pneumonitis.
  • Concurrent Treatment:
  • Allowed:
  • Intravenous hyperalimentation.
  • Patients must have the following:
  • P-2 class symptomatic HIV infection as defined by CDC OR who are asymptomatic but whose total CD4 cell count is < 500 cells/mm3.
  • Freedom from significant active opportunistic or other infection requiring specific therapy.
  • Part B patients:
  • Prior treatment with zidovudine (AZT) that was discontinued because of hematologic toxicity.
  • Availability of a parent or legal guardian who is sufficiently reliable to give informed consent and follow necessary study procedures including administration of medications and return for follow-up visits.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following conditions or symptoms are excluded:
  • Critically ill, clinically unstable, or receiving drug therapy for an opportunistic or other infection.
  • History of acute or chronic pancreatitis.
  • Patients with the following are excluded:
  • Critically ill, clinically unstable, or receiving drug therapy for an opportunistic or other infection.
  • History of acute or chronic pancreatitis.
  • Prior Medication:
  • Excluded:
  • Antiretroviral or other antiviral agent within 14 days of entry into study.
  • Immunomodulating agents, cytolytic chemotherapeutic agents, corticosteroids within 30 days (except for lymphocytic interstitial pneumonitis).
  • Part A patients:
  • Zidovudine (AZT) or didanosine (ddI).
  • Part B patients:
  • Didanosine (ddI).
  • Prior Treatment:
  • Excluded:
  • Radiation therapy within 30 days.
  • Intravenous immunoglobulin preparations within 14 days of entry into study.

Attachments

readout_NCT00000652_2023-12-10.pdf

4.5 MB

NCT00000652_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Los Angeles, California, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0